1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. This funding opportunity focuses on establishing or supporting Digestive Diseases Research Core Centers.
These centers provide shared resources to enhance the efficiency, productivity, and multidisciplinary interactions of digestive disease researchers.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Silvio O Conte Digestive Diseases Research Core Centers Application Resources (P30) - NIDDK Silvio O Conte Digestive Diseases Research Core Centers Application Resources (P30) Silvio O Conte Digestive Diseases Research Core Centers Application Resources (P30) Most recent NIDDK funding announcement: RFA-DK-25-003 The NIDDK-supported Digestive Diseases Research Core Centers (DDRCC) are part of an integrated program of support for basic and clinical research in digestive and liver diseases.
Tables for P30 DDRCC Applications Applicants are strongly encouraged to use the following tables as part of their DDRCC application. Please download the files (. xlsx formats) and complete them as directed.
Table A: Summary of Current and Pending Grant Support of all Center Members Table B: Listing of all Center Members and their Core Facility Use (XLSX, 19. 31 KB) Table C: Collaborations between Center Members (XLSX, 19. 1 KB) Table D: Core Facility Use (XLSX, 25.
44 KB) Table E: Pilot Project Outcomes (XLSX, 20. 27 KB) Table F: Consolidated Publication List (XLSX, 21. 73 KB) * Documents in Excel format require Microsoft Office applications for viewing.
Electronic Submission of Grant Applications The DDRCC program, like all DK-Center programs, has transitioned to electronic submission of New, Renewal, and Resubmission applications. 30 days prior to the application due date
According to the current listing, eligibility includes: Not specified in snippet, but P30 grants typically support institutions. Confirm the full requirements in the official notice before applying.
Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional) is funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs from NIDDK are competitive federal grant programs administered by the National Institute of Diabetes and Digestive and Kidney Diseases supporting innovative research by small businesses with potential for commercialization. NIDDK participates in both SBIR and STTR programs, with funding opportunities aligned to its mission areas in diabetes, digestive diseases, and kidney diseases. Eligible applicants are U.S. small businesses with innovative research applicable to NIDDK's scientific program areas. The NIH SEED website provides comprehensive application guidance and NIDDK-specific program contacts.
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. This program encourages applications to plan multi-center clinical studies. While not specific to bioartificial kidneys, research planning for such complex medical devices would fall under clinical study implementation.
NIDDK High Risk, High Impact Research is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. NIDDK supports high-risk, high-impact research to advance understanding and treatment of kidney diseases. Development of a bioartificial kidney would be considered high-impact research. This would likely be pursued through general NIH funding mechanisms (e.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article